A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

NCT00000779 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Aluminum hydroxide
BIOLOGICAL: MF59
BIOLOGICAL: rgp120/HIV-1IIIB
BIOLOGICAL: rgp120/HIV-1MN
BIOLOGICAL: rgp120/HIV-1 SF-2
BIOLOGICAL: Env 2-3

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)